Clinical Trial Update: Clinical Safety Study on 5-Aminolevulinic Acid (5-ALA) in Children and Adolescents With Brain Tumors [Phase 2]

View source ↗

Summary

Phase 2 safety study of 5-aminolevulinic acid (5-ALA) in children and adolescents with brain tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Tumor

Drugs mentioned

• 5-ALA (5-aminolevulinic acid) (5-aminolevulinic acid)

Snippet

Sponsor: Universität Münster | Conditions: Brain Tumor, Pediatric | Phase 2 | Status: COMPLETED